Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
The investigators want to know if ultra-short, effective treatment for latent tuberculosis
(TB) infection (LTBI) could dramatically reduce the global incidence of active TB or not. The
investigators hypothesize that short-course (4-week) daily isoniazid/rifapentine (INH/RPT)
(1HP) is not inferior to standard -course (12 weeks) INH/RPT weekly regimen (3HP) for the
prevention of TB in human immunodeficiency virus (HIV)-infected individuals.
Phase:
Phase 3
Details
Lead Sponsor:
The HIV Netherlands Australia Thailand Research Collaboration
Collaborators:
Bhumibol Adulyadej Hospital Buddhachinnaraj Hospital Chiang Rai Prachanukroh Hospital Hatyai Hospital King Chulalongkorn Memorial Hospital Klang Hospital Maharat Nakhon Ratchasima Hospital Police General Hospital Pranangklao Hospital Queen Sawang Vadhana Memorial Hospital Sanpatong Hospital Sisaket Hospital Srinagarind Hospital, Khon Kaen University Taksin Hospital The Public Health Centre 28 Krung thon buri
Treatments:
Isoniazid Pyridoxal Pyridoxine Rifampin Rifapentine Vitamin B 6 Vitamin B Complex Vitamins